Hutchison China Meditech Limited Results of Annual General Meeting (5842D)

TIDMHCM

RNS Number : 5842D

Hutchison China Meditech Limited

27 April 2017

Results of Annual General Meeting

London: Thursday, April 27, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ("AGM") held on April 27, 2017 were duly passed. The poll results of the resolutions were as follows:

 
                                                                Number of Votes (%)* 
 
   Resolutions                                            For          Against      Withheld(#) 
      To consider and adopt the 
       audited financial statements 
       and the reports of the 
       directors and independent 
       auditor for the year ended 
 1     31 December 2016.                              50,428,039        80              4 
                                                      (99.99984%)    (0.00016%) 
 
      To re-elect Mr Paul Carter 
 2     as a director.                                 50,427,873        50             200 
                                                      (99.99990%)    (0.00010%) 
 
      To re-elect Mr Johnny Cheng 
 3     as a director.                                 50,405,806      22,116           201 
                                                      (99.95614%)    (0.04386%) 
 
      To re-elect Dr Dan Eldar 
 4     as a director.                                 50,405,776      21,785           562 
                                                      (99.95680%)    (0.04320%) 
 
      To re-elect Dr Karen Ferrante 
 5     as a director.                                 50,427,873        50             200 
                                                      (99.99990%)    (0.00010%) 
 
      To re-elect Mr Graeme Jack 
 6     as a director.                                 50,426,736       1,186           201 
                                                      (99.99765%)    (0.00235%) 
 
      To re-elect Ms Edith Shih 
 7     as a director.                                 50,405,776      21,785           562 
                                                      (99.95680%)    (0.04320%) 
 
      To re-elect Dr Weiguo Su 
 8     as a director.                                 50,406,168      21,755           200 
                                                      (99.95686%)    (0.04314%) 
 
      To re-appoint PricewaterhouseCoopers 
       as the auditor of the Company 
       and authorise the board 
       of directors to fix the 
 9     auditor's remuneration.                        50,424,313       3,380           430 
                                                      (99.99330%)    (0.00670%) 
 
                                To grant 
                                 a general 
                                 mandate to 
                                 the directors 
                                 of the Company 
                                 to issue 
      Ordinary Resolution        additional 
 10    No. 10(A)            :    shares.              50,423,856       3,913           354 
                                                      (99.99224%)    (0.00776%) 
 
                                To disapply 
                                 pre-emption 
      Special Resolution         rights (Equity 
       No. 10(B)            :    Raise).              45,969,701     4,457,156        1,266 
                                                      (91.16115%)    (8.83885%) 
 
                                To disapply 
      Special Resolution         pre-emption 
       No. 10(C)            :    rights (general).    48,240,334     2,186,523        1,266 
                                                      (95.66397%)    (4.33603%) 
 
                                To grant 
                                 a general 
                                 mandate to 
                                 the directors 
                                 of the Company 
                                 to repurchase 
      Ordinary Resolution        shares of 
       No. 10(D)            :    the Company.         50,427,589        333            201 
                                                      (99.99934%)    (0.00066%) 
 

* Percentages rounded to 5 decimal places

(#) A vote withheld is not a vote in law and is not counted in the calculation of the proportion of the votes for and againsta resolution.

As at the date of the AGM, the number of issued shares of Chi-Med was 60,726,979, which was the total number of shares entitling the holders to attend and vote on the ordinary resolutions and special resolutions proposed at the AGM.

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 0001). For more information, please visit: www.chi-med.com.

CONTACTS

 
Investor Enquiries 
Christian Hogg, CEO                        [phone] 
 
U.K. & International Media Enquiries 
Anthony Carlisle, Citigate Dewe Rogerson   [phone] (Mobile)   [e-mail] 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications             [phone] (Mobile)  [e-mail] 
Susan Duffy, BMC Communications            [phone] (Mobile)  [e-mail] 
 
Investor Relations 
Matt Beck, The Trout Group                 [phone] (Mobile)  [e-mail] 
David Dible, Citigate Dewe Rogerson        [phone] (Mobile)   [e-mail] 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts                [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGSEDFDWFWSESL

(END) Dow Jones Newswires

April 27, 2017 09:10 ET (13:10 GMT)